2018
DOI: 10.1002/med.21545
|View full text |Cite
|
Sign up to set email alerts
|

Norovirus antivirals: Where are we now?

Abstract: Human noroviruses inflict a significant health burden on society and are responsible for approximately 699 million infections and over 200 000 estimated deaths worldwide each year. Yet despite significant research efforts, approved vaccines or antivirals to combat this pathogen are still lacking. Safe and effective antivirals are not available, particularly for chronically infected immunocompromised individuals, and for prophylactic applications to protect high-Med Res Rev. 2019;39:860-886. wileyonlinelibrary.… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
50
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 68 publications
(50 citation statements)
references
References 195 publications
0
50
0
Order By: Relevance
“…For norovirus, the recent development of a cell culture system implies the opportunity to investigate antivirals. Several substances have been proposed as possible candidates, including ribavirin and nitazoxanide 207 . Therapeutic possibilities for norovirus could reduce the morbidity for HSCT patients, and other immunocompromised patients, with chronic norovirus infection.…”
Section: Treatment Possibilitiesmentioning
confidence: 99%
“…For norovirus, the recent development of a cell culture system implies the opportunity to investigate antivirals. Several substances have been proposed as possible candidates, including ribavirin and nitazoxanide 207 . Therapeutic possibilities for norovirus could reduce the morbidity for HSCT patients, and other immunocompromised patients, with chronic norovirus infection.…”
Section: Treatment Possibilitiesmentioning
confidence: 99%
“…Several factors have hindered the development of broadly protective HuNoV vaccines and treatment, including the marked antigenic diversity of norovirus strains and an incomplete understanding of protective immunity [15]. This review aims to summarize the collective data of norovirus epitope mapping studies in order to elucidate common features of strain-specific and cross-reactive antigenic sites.…”
Section: Introductionmentioning
confidence: 99%
“…Norovirus can be life-threatening to children, especially undernourished children from developing countries [152], infants, older adults, and immunocompromised individuals [151]. There are no clinically approved antivirals and vaccines for norovirus infections [153] since the challenge is that the virus presents with a vast genetic diversity, with over thirty different genotypes infecting humans [151].…”
Section: Norovirusmentioning
confidence: 99%